Advertisement

Related Videos

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Focus on Optimized Dosing of Ibrutinib Panel Discussion

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Advertisement

Advertisement




May
10
Today In Oncology
FDA Approves Zenocutuzumab-zbco for Advanced, Unresectable, or Metastatic Cholangiocarcinoma
Long-Term Outcomes With Maintenance Rucaparib in Advanced Pancreatic Cancer With BRCA or PALB2 Pathogenic Variants
Tiragolumab Plus Atezolizumab and Chemotherapy in Advanced Nonsquamous NSCLC
Appendiceal Cancer: Serum Tumor Marker Levels May Guide Treatment in Patients Undergoing CRS
High YAP1 Expression Leads to Chemotherapy Resistance Relapse in Treated SCLC
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo